EXECUTIVE ENGAGEMENTS
POOL
16256
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1626
Interactions with Platform & by Email
PARTICIPANTS
323
Unique # Participated
VALIDATIONS
81
Responses Validated*
COMPANIES
87
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
54
PAGES
171
EDITION
20
PRICE
USD 5450
CODE
MCP-7877
*Engagement stats are ongoing and dynamic
Sign-in with email to View Deeper Validated Engagement Details -
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Personalized Medicines estimated at US$227.9 Billion in the year 2020, is projected to reach a revised size of US$515.3 Billion by 2027, growing at aCAGR of 12.4% over the period 2020-2027. Tests & Lab Services, one of the segments analyzed in the report, is projected to record 11.3% CAGR and reach US$296.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Targeted Therapeutics segment is readjusted to a revised 13.9% CAGR for the next 7-year period.
The Personalized Medicines market in the U.S. is estimated at US$67.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$90.5 Billion by the year 2027 trailing a CAGR of 12% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.7% and 10.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR.
SELECT PLAYERS
Abbott Molecular; Beckman Coulter, Inc.; bioMérieux SA; Bristol-Myers Squibb Company; Dako Denmark A/S; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc; Hologic, Inc.; Lab 21 Limited; Macrogen, Inc.; NeoGenomics Laboratories, Inc.; Novartis AG; QIAGEN NV; Rosetta Genomics Ltd.; Thermo Fischer Scientific Inc.
SEGMENTS
» Type (Tests & Lab Services, Targeted Therapeutics)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Access to Valuable Genetic Information Ushers Transformation in Medicine |
| Recent Market Activity |
| Market Outlook |
| Adoption of Personalized Medicines - A Peek into Developed and Developing Economies |
| Increasing Market Availability of Personalized Medicines |
| Select Key Approved Personalized Medicines and Associated Biomarkers by Therapeutic Area |
| Constraints in Traditional Approach to Treatment Creates Need and Demand for Personalized Medicine |
| Economics of Personalized Medicine |
| Is Emergence of Personalized Medicine Signaling the End of Blockbusters? |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Abbott Molecular, Inc. (USA) |
| Beckman Coulter Genomics (USA) |
| bioMérieux SA (France) |
| Bristol-Myers Squibb Company (USA) |
| Dako Denmark A/S (Denmark) |
| F. Hoffmann-La Roche Ltd. (Switzerland) |
| GlaxoSmithKline plc. (UK) |
| Hologic, Inc. (USA) |
| Lab 21 Limited (UK) |
| Macrogen, Inc. (Korea) |
| NeoGenomics Laboratories, Inc. (USA) |
| Novartis AG (Switzerland) |
| QIAGEN NV (The Netherlands) |
| Rosetta Genomics Ltd (Israel) |
| Thermo Fisher Scientific Inc. (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Growth Drivers in a Gist |
| Key Market Restraints |
| Increasing Incidence and Prevalence of CDDs: A Major Growth Driver |
| Oncology - A Major Application Market |
| Diagnosed Cases of Cancer on the Rise |
| World Cancer Statistics: Incidence and Mortality Data |
| Growing Cancer Cases in Developing Countries Bodes Well for the Personalized Medicine Market |
| Growing Importance of Personalized Drugs for Cancer Treatment |
| Ballooning Global Population Offers Significant Growth Opportunities |
| Aging Global Population Drives Personalized Medicines |
| Increasing Healthcare Spending in Emerging Markets |
| Changing Patients' Trends Drive Personalized Medicine |
| Technological Advancements and Consumer Push to Drive Personalized Medicine |
| Minimizing Adverse Events - A Major Benefit of Personalized Medicines |
| Personalized Medicines Brings Disease Prevention Closer to Reality |
| Ability to Manage Healthcare Costs Piques Industry and Government Alike |
| Potential to Uncover Additional Prospective Targets - A Major Benefit in Pursuit |
| Elimination of Invasive Tests Attracts Patients and Doctors towards Molecular Test-based Personalized Medicines |
| Genomics to Dictate Advancement of Personalized Medicines |
| Companion Diagnostics Drive Personalized Medicine |
| Biomarkers as Companion Diagnostics |
| Personalized Medicines Help Reducing R&D Costs |
| Personalized Medicine - A Corporate Growth Strategy |
| Development Pipeline Reveals Promising Picture for Personalized Medicine |
| Advancements in Biomedical Imaging to Enhance Personalized Medicines |
| Increasing Use of Personalized Medicines Drives Genetic Testing |
| Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market |
| Next-Generation Sequencing - A Giant Leap in Genome Sequencing |
| Single Nucleotide Polymorphism (SNP) - Making Advancements in Personalized Medicine |
| Personalized Medicine Goes Beyond DNA Analysis |
| Combination Approaches May Mark Future Endeavors |
| Need for New Designs in Clinical Trials Emerges in Therapies for Rare Cancers |
| Immunotherapy for Cancers - A Potential Breakthrough in the Sector |
| Personalized Medicine Industry - Inundated with Data |
| Advanced Computing Technologies - The Need of The Hour to Analyze Large Data |
| Artificial Intelligence Revolutionizing Personalized Medicine |
| Challenges Aplenty for Precision Medicine |
| Lack of Clinically Useful Diagnostic Tests - Growth Dampener |
| Pricing and Value Dilemma Haunts Personalized Medicines |
| Bedside Biopharmaceutical Production to Dramatically Reduce Cost of Personalized Medicine |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Personalized Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Personalized Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Tests & Lab Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Tests & Lab Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Tests & Lab Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Personalized Medicines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Personalized Medicines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Personalized Medicines by Type - Tests & Lab Services and Targeted Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Personalized Medicines by Type - Percentage Breakdown of Value Sales for Tests & Lab Services and Targeted Therapeutics for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 87 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com